{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:35:26Z","timestamp":1793018126381,"version":"4.5.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13555-026-01947-z","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:29:04Z","timestamp":1791379744000},"page":"5855-5862","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Topical Delgocitinib for Capecitabine-Induced Hand\u2013Foot Syndrome: A Therapeutic Option?"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4029-941X","authenticated-orcid":false,"given":"Luca","family":"Rapparini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9310-870X","authenticated-orcid":false,"given":"Ginevra","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9783-7864","authenticated-orcid":false,"given":"Stephano","family":"Cedirian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2931-767X","authenticated-orcid":false,"given":"Francesca","family":"Pampaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-425X","authenticated-orcid":false,"given":"Francesca","family":"Bruni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3981-1527","authenticated-orcid":false,"given":"Michela","family":"Starace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"issue":"10","key":"1947_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-025-06319-2","volume":"151","author":"B Chen","year":"2025","unstructured":"Chen B, Wang X, Meng L. Advancements in the diagnosis and management of capecitabine-induced hand-foot syndrome. J Cancer Res Clin Oncol. 2025;151(10):265.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"1947_CR2","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1007\/s10147-025-02895-y","volume":"30","author":"Y Iimura","year":"2025","unstructured":"Iimura Y, Iihara H, Saito Y, et al. Chemotherapy-related hand-foot syndrome and hand-foot skin reaction: a review of management and possible approaches for Asian patients by the Japanese pharmacist-led oncodermatology study team. Int J Clin Oncol. 2025;30(12):2474\u201388.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"1947_CR3","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1634\/theoncologist.2011-0033","volume":"16","author":"V Sibaud","year":"2011","unstructured":"Sibaud V, Dalenc F, Chevreau C, et al. HFS-14, a specific quality of life scale developed for patients suffering from hand\u2013foot syndrome. Oncologist. 2011;16(10):1469\u201378.","journal-title":"Oncologist"},{"issue":"3","key":"1947_CR4","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/spcare-2025-005639","volume":"16","author":"M Saeteaw","year":"2026","unstructured":"Saeteaw M, Thippharak T, Porasuntisuk K, Kengkla K, Chan A, Subongkot S. Hand-foot syndrome prevention: pharmacological interventions-systematic review and network meta-analysis. BMJ Support Palliat Care. 2026;16(3):540\u20137.","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"1947_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s40265-025-02262-1","volume":"86","author":"D Termini","year":"2026","unstructured":"Termini D, Avallone G, Tavoletti G, et al. Pan-JAK inhibition across chronic hand eczema and other cutaneous diseases: an updated review on topical delgocitinib. Drugs. 2026;86(1):59\u201377.","journal-title":"Drugs"},{"issue":"1","key":"1947_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40257-025-00974-4","volume":"27","author":"R Bissonnette","year":"2026","unstructured":"Bissonnette R, Albreiki F, Ehst BD, et al. Summary of research: efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2): results from multicentre, randomised, controlled, double-blind, phase\u00a03 trials. Am J Clin Dermatol. 2026;27(1):199\u2013202.","journal-title":"Am J Clin Dermatol"},{"issue":"10490","key":"1947_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/S0140-6736(25)00001-7","volume":"405","author":"AM Gim\u00e9nez-Arnau","year":"2025","unstructured":"Gim\u00e9nez-Arnau AM, Pinter A, Sondermann W, et al. Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase\u00a03 trial. Lancet. 2025;405(10490):1676\u201388.","journal-title":"Lancet"},{"issue":"3","key":"1947_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1021\/acs.chemrestox.1c00317","volume":"35","author":"X He","year":"2022","unstructured":"He X, Wang J, Wang Q, et al. P38 MAPK, NF-\u03baB, and JAK-STAT3 signaling pathways involved in capecitabine-induced hand-foot syndrome via interleukin 6 or interleukin 8 abnormal expression. Chem Res Toxicol. 2022;35(3):422\u201330.","journal-title":"Chem Res Toxicol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01947-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01947-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:06:34Z","timestamp":1793016394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01947-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01947-z","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"assertion":[{"value":"25 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michela Starace is an Editorial Board member of\n                      Dermatology and Therapy\n                      . Michela Starace was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Luca Rapparini, Ginevra Martelli, Stephano Cedirian, Francesca Pampaloni, and Francesca Bruni have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patients in this manuscript have given written informed consent to the publication of their case details and photos according to the Declaration of Helsinki principles. As delgocitinib was used off-label for capecitabine-induced HFS, both patients also provided written informed consent for its off-label use, in accordance with the institutional procedure for off-label treatment. No ethical approval is required. Formal ethics committee approval was not required because this report describes the observation of two patients treated in routine clinical practice and did not involve any prospective experimental intervention or study-specific procedure.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}